Cancer (Photo: ShutterStock)
The Israeli company Biolojic Design has developed smart antibodies that use artificial intelligence (AI) to treat cancer.
Biologic Design uses artificial intelligence technology to eliminate various diseases, such as cancer, when a few months ago it began an experiment on humans in Australia through the company Aulos Biosciences (a joint venture between Biologic Design and the ATP venture capital fund).
The founder and CEO of the company is Professor Yanai Ofran.
At Biologic Design, they realized that the reason that the drugs trying to cure cancer failed, is that these are simple molecular drugs, which only know how to interfere with the biological process.
In addition, they also damage other processes in the body, even though the main goal is to damage cancer.
Biologic Design's solution is the use of artificial intelligence to design drugs with smart molecules, which do not harm different parts of the body indiscriminately, but drugs that measure the cell before harming it, with the aim of understanding whether it is cancerous or not and to provide precise and targeted treatment, which is also very effective More.
Biologic Design programs the antibodies like a computer program, develops and designs the antibodies in a precise way to attack the causes of the diseases, all this allows, among other things, to damage infected tissues without harming healthy tissues.
The computer technology mimics the way the immune system produces antibodies and turns the cell into hardware and the antibody into software.
Melanoma cancer cells (provided as a public service sponsored by BMS)
The field of artificial intelligence is gaining a lot of popularity thanks to ChatGPT and the capabilities it brings to people, but this technology is also revolutionizing the pharmaceutical world.
"The previous generation of computer search tools worked like Google: the computer could search among the existing documents for the document most similar to the query. For example, if you searched for a song about Tel Aviv in the rain, it would look for a song in which the words "Tel Aviv" and "rain" appear. On the way At all, the result didn't hit exactly what you wanted, for example the song was sad and you wanted a happy song, but this was the most appropriate result among the existing songs," says Ofran, "Artificial intelligence has revolutionized: today you can ask ChatGPT for a happy song about Tel Aviv in the rain And he will write you a special song with a rhyme and weight that meets all your requirements, and maybe even mentions the name of your company.
"A similar revolution is taking place today in the world of drug development. The previous generation of computational tools allowed drug developers to scan the molecules known to science and locate among them a molecule that has similar characteristics to what the researcher is looking for. For example, if you were looking for a molecule that attacks cancer, you might be able to find a molecule that attacks cancer but attacks Healthy tissues too. This is the best molecule among the known molecules and we had to settle for it. Artificial intelligence, on the other hand, today allows us to design molecules that are not yet known and may not even exist yet but have all the characteristics we are looking for. For example, to attack the disease in a precise and safe way And effective, exactly at the right time. These drugs will be more precise, safer and more effective."
The development of the artificial intelligence (AI) platform that uses computational biology and big data to design an antibody specific to epitopes, was carried out over the past 10 years by Yanai Ofran, founder and CEO of Biolojic Design. The goal of the development is to design antibodies that know how to provide targeted and precise treatment on the function of
"Unlike antibodies produced by conventional antibody technologies, our approach promises the development of smart antibodies
This is a type of nanorobots, which, like natural proteins, are able to adapt to changing situations," Ofran says. "We have finally reached a stage where an antibody developed on a computer can be used in humans.
Thanks to our work with Aulos Bioscience, a subsidiary of Biologic Design, we will be able to inject human patients with the first computer-designed antibody in history."